Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating luvadaxistat for cognitive impairment in schizophrenia has been terminated. The trial was sponsored by Neurocrine Biosciences.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Luvadaxistat (luvadaxistat)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED